Literature DB >> 27773982

Review: Hemodynamic Characteristics and Outcomes of Sickle Cell Disease Associated Pulmonary Hypertension.

Alem Mehari1, Alvin V Thomas1, Alicia N Thomas1, Mark S Johnson2.   

Abstract

Pulmonary hypertension (PH) is a leading cause of morbidity and early mortality in adults with sickle cell disease (SCD). However, the prevalence, hemodynamic profile and prognosis of SCD-PH remain controversial and need frequent updates. Pulmonary hypertension determined by right heart catheterization (RHC) occurs in 6% to 10% of adults with SCD. Hemodynamically, SCD-PH may be pre-capillary or post-capillary in nature. The exact etiology is unknown and often multifactorial; hence a thorough diagnostic evaluation following established PH guidelines is essential to determine disease prevalence, etiology and outcomes. Data on the efficacy and safety of pulmonary arterial hypertension (PAH) therapy are limited in SCD; clinical trials in these patients are urgently needed. This review provides an overview of RHC-determined hemodynamic characteristics, current management modality and outcomes; we also highlight recent advances and unmet research needs in SCD-PH.

Entities:  

Keywords:  Hemodynamics; Pulmonary Hypertension; Sickle Cell Disease

Mesh:

Year:  2016        PMID: 27773982      PMCID: PMC5072484          DOI: 10.18865/ed.26.4.545

Source DB:  PubMed          Journal:  Ethn Dis        ISSN: 1049-510X            Impact factor:   1.847


  56 in total

1.  Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies.

Authors:  Robyn J Barst; Kamal K Mubarak; Roberto F Machado; Kenneth I Ataga; Raymond L Benza; Oswaldo Castro; Robert Naeije; Namita Sood; Paul S Swerdlow; Mariana Hildesheim; Mark T Gladwin
Journal:  Br J Haematol       Date:  2010-02-17       Impact factor: 6.998

2.  Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

Authors:  Gregory J Kato; Vicki McGowan; Roberto F Machado; Jane A Little; James Taylor; Claudia R Morris; James S Nichols; Xunde Wang; Mirjana Poljakovic; Sidney M Morris; Mark T Gladwin
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

3.  Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension.

Authors:  Roberto F Machado; Sabrina Martyr; Gregory J Kato; Robyn J Barst; Anastasia Anthi; Michael R Robinson; Lori Hunter; Wynona Coles; James Nichols; Christian Hunter; Vandana Sachdev; Oswaldo Castro; Mark T Gladwin
Journal:  Br J Haematol       Date:  2005-08       Impact factor: 6.998

4.  Mortality in adults with sickle cell disease and pulmonary hypertension.

Authors:  Alem Mehari; Mark T Gladwin; Xin Tian; Roberto F Machado; Gregory J Kato
Journal:  JAMA       Date:  2012-03-28       Impact factor: 56.272

5.  N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease.

Authors:  Roberto F Machado; Anastasia Anthi; Martin H Steinberg; Duane Bonds; Vandana Sachdev; Gregory J Kato; Angelo M Taveira-DaSilva; Samir K Ballas; William Blackwelder; Xiuli Xu; Lori Hunter; Bruce Barton; Myron Waclawiw; Oswaldo Castro; Mark T Gladwin
Journal:  JAMA       Date:  2006-07-19       Impact factor: 56.272

Review 6.  [Pulmonary arterial hypertension associated with common diseases: connective-tissue diseases, HIV infection and portal hypertension].

Authors:  Olivier Sitbon; Xavier Jaïs; Jérôme Le Pavec; Bruno Degano; Marc Humbert; Gérald Simonneau
Journal:  Rev Prat       Date:  2008-11-30

7.  Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease.

Authors:  Caterina P Minniti; Roberto F Machado; Wynona A Coles; Vandana Sachdev; Mark T Gladwin; Gregory J Kato
Journal:  Br J Haematol       Date:  2009-09-22       Impact factor: 6.998

8.  Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.

Authors:  Stephen C Mathai; Laura K Hummers; Hunter C Champion; Fredrick M Wigley; Ari Zaiman; Paul M Hassoun; Reda E Girgis
Journal:  Arthritis Rheum       Date:  2009-02

9.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

10.  Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations.

Authors:  Ersi Voskaridou; George Tsetsos; Antonios Tsoutsias; Evgenia Spyropoulou; Dimitrios Christoulas; Evangelos Terpos
Journal:  Haematologica       Date:  2007-06       Impact factor: 9.941

View more
  1 in total

1.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; David Montani; David S Celermajer; Christopher P Denton; Michael A Gatzoulis; Michael Krowka; Paul G Williams; Rogerio Souza
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.